HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Switzerland Reclassifies Rx Drugs For Migraine And Pain

Executive Summary

Switzerland has added treatments for migraine and acute pain to the list of Rx drugs permitted for sale without prescription in pharmacy.

You may also be interested in...



Switzerland Approves Raft Of Rx-To-OTC Switches

Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.

Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

Swiss medicines authority, Swissmedic, rules that hundreds of non-prescription medicines are safe to be purchased outside pharmacy, following the completion of its review of the country's medicines classification system.

UK Industry Preparing Response To ‘Wide Ranging’ Medical Devices Consultation

UK consumer healthcare industry association PAGB is preparing its response to a "wide ranging" consultation on the future of how medical devices are regulated in the country. MHRA says it wants a system that streamlines product approvals while still prioritizing patient safety.

Topics

UsernamePublicRestriction

Register

RS151585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel